Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2017

View Archived Issues

DelSiTech and C-TRI to jointly develop long-acting controlled release formulations

Bioharmony Therapeutics receives support to develop lysins for bacterial infections

BeiGene begins phase II study of pamiparib

Twin epigenetic study reveals idiopathic epilepsy biomarkers

Array BioPharma and Pfizer to jointly test several cancer drug combinations

Shire reports topline results from phase II/III study of SHP-609

Pilot clinical study of Aclaris Therapeutics' ATI-50002 in vitiligo begins

REGENXBIO's IND for study of RGX-121 in MPS II now active

Elacestrant significantly reduced FES uptake in patients with ER+/HER2- breast cancer

Bispecific antibody targeting [90Y]-DOTA and CD45 may enhance radiotherapy for leukemia

Critical Outcome Technologies' COTI-2 safe, well tolerated in phase I study

FDA gives fast track designation to Ovid Therapeutics' OV-101 for Angelman syndrome

Novel P2X3 and/or P2X2/3 receptor antagonists identified at Shionogi

First patient screened in Minerva Neurosciences' phase III study of MIN-101

GlycoMimetics patents novel E-selectin binding inhibitors

BioMarin initiates first phase III study of valoctocogene roxaparvovec for severe hemophilia A

Transcriptx presents nucleic acids encodingdynein intermediate chain 1, axonemal

Updated phase II data for tetrathiomolybdate in patients with breast cancer at risk for recurrence

FDA approves Luxturna gene therapy for biallelic RPE65 mutation-associated retinal dystrophy

Faron Pharmaceuticals cleared to continue INFORAAA study of Traumakine

FDA approves Cabometyx for previously untreated advanced RCC

Second Genome's lead candidate demonstrates safety, tolerability in phase I study

Solid Biosciences initiates phase I/II study of SGT-001 in Duchenne muscular dystrophy

Otsuka and X-Chem sign collaborative research agreement

Onconova and HanX enter license and collaborative development agreement for ON-123300

FDA approves Prexxartan

Promising results for novel anti-EGFR radiotracer in patients with non-small cell lung cancer

FDA accepts for review BLA for Samsung Bioepis' trastuzumab biosimilar

FDA approves Bosulif for newly diagnosed Ph+ CML

Biogen and Ionis enter new collaboration for SMA

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...